pulmoПульмонологияPULMONOLOGIYA0869-01892541-9617Scientific and Practical Journal “PULMONOLOGIYA” LLC10.18093/0869-0189-2010-2-49-55pulmo-1627Research ArticleСтатьиРоль С-реактивного белка в диагностике бактериальной инфекции и пневмонии у пациентов с обострением хронической обструктивной болезни легкихАвдеевС. Н.noemail@neicon.ruБаймакановаГ. Е.noemail@neicon.ruЗубаироваП. А.noemail@neicon.ruЧучалинА. Г.noemail@neicon.ruФГУ "НИИ пульмонологии ФМБА России"Russian Federation201028042010024955Copyright © Авдеев С.Н., Баймаканова Г.Е., Зубаирова П.А., Чучалин А.Г., 20102010Авдеев С.Н., Баймаканова Г.Е., Зубаирова П.А., Чучалин А.Г.Авдеев С.Н., Баймаканова Г.Е., Зубаирова П.А., Чучалин А.Г.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://journal.pulmonology.ru/pulm/article/view/1627

Целью исследования было изучение роли С-реактивного белка (СРБ) в диагностике бактериальных инфекций и пневмонии при обострении хронической обструктивной болезни легких (ХОБЛ). Были обследованы 123 пациента (средний возраст - 65,4 ± 48,8 года, индекс курения - 42,8 ± 14,3 пачки / лет), госпитализированных в стационар с обострением ХОБЛ. Уровень СРБ в крови измеряли с помощью системы NycoCard II Test Kit (AxisShield, Норвегия). У 23 больных с обострением ХОБЛ диагностирована пневмония. Концентрация сывороточного СРБ у больных пневмонией была выше, чем у пациентов без пневмонии (105,8 ± 66,1 мг/л; p < 0,001). У пациентов без продукции гнойной мокроты (n = 26) уровень СРБ был ниже, чем у больных с продукцией гнойной мокроты (n = 74): 12,1 ± 7,0 мг/л vs 34,5 ± 18,8 мг/л (p < 0,001). СРБ является ценным маркером бактериальной инфекции и пневмонии у больных с обострением ХОБЛ, что важно для разработки тактики лечения данной категории пациентов.

обострение хронической обструктивной болезни легкихС-реактивный белокпневмониябактериальные инфекцииReferencesGlobal Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI / WHO workshop report. The 2008 report is available on www.goldcopd.com.Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI / WHO workshop report. The 2008 report is available on www.goldcopd.com.Celli B.R., Barnes P.J. Exacerbation of chronic obstructive pulmonary disease. Eur. Respir. J. 2007; 29: 1224-1238.Celli B.R., Barnes P.J. Exacerbation of chronic obstructive pulmonary disease. Eur. Respir. J. 2007; 29: 1224-1238.Sethi S., Murphy T.F. Infection in the pathogenesis and course of chronic obstructive pulmonary disease. N. Engl. J. Med. 2008; 359: 2355-2365.Sethi S., Murphy T.F. Infection in the pathogenesis and course of chronic obstructive pulmonary disease. N. Engl. J. Med. 2008; 359: 2355-2365.Pinto-Plata V.M., Livnat G., Girish M. et al. Systemic cytokines, clinical and physiological changes in patients hospitalized for exacerbation of COPD. Chest 2007; 131: 37-43.Pinto-Plata V.M., Livnat G., Girish M. et al. Systemic cytokines, clinical and physiological changes in patients hospitalized for exacerbation of COPD. Chest 2007; 131: 37-43.Fagon J.Y., Chastre J., Trouillet J.L. et al. Characterization of distal bronchial microflora during acute exacerbation of chronic bronchitis: use of the protected specimen brush technique in 54 mechanically ventilated patients. Am. Rev. Respir. Dis. 1990; 142: 1004-1008.Fagon J.Y., Chastre J., Trouillet J.L. et al. Characterization of distal bronchial microflora during acute exacerbation of chronic bronchitis: use of the protected specimen brush technique in 54 mechanically ventilated patients. Am. Rev. Respir. Dis. 1990; 142: 1004-1008.Авдеев С.Н., Баймаканова Г.Е., Зубаирова П.А., Чучалин А.Г. Пневмония как причина острой дыхательной недостаточности у больных ХОБЛ. Пульмонология 2006; 5: 115-121.Авдеев С.Н., Баймаканова Г.Е., Зубаирова П.А., Чучалин А.Г. Пневмония как причина острой дыхательной недостаточности у больных ХОБЛ. Пульмонология 2006; 5: 115-121.Farr B.M., Kaiser D.L., Harrison B.D., Connolly C.K. Prediction of microbial aetiology at admission to hospital for pneumonia from the presenting clinical features. British Thoracic Society Pneumonia Research Subcommittee. Thorax 1989; 44: 1031-1035.Farr B.M., Kaiser D.L., Harrison B.D., Connolly C.K. Prediction of microbial aetiology at admission to hospital for pneumonia from the presenting clinical features. British Thoracic Society Pneumonia Research Subcommittee. Thorax 1989; 44: 1031-1035.Баймаканова Г.Е., Зубаирова П.А., Авдеев С.Н., Чучалин А.Г. Особенности клинической картины и течения внебольничной пневмонии у пациентов с хронической обструктивной болезнью легких. Пульмонология 2009; 2: 33-41.Баймаканова Г.Е., Зубаирова П.А., Авдеев С.Н., Чучалин А.Г. Особенности клинической картины и течения внебольничной пневмонии у пациентов с хронической обструктивной болезнью легких. Пульмонология 2009; 2: 33-41.Dev D., Sankaran E.W.R., Cunnife J. et al. Value of C-reactive protein in exacerbation of chronic obstructive pulmonary disease. Respir. Med. 1998; 92: 664-667.Dev D., Sankaran E.W.R., Cunnife J. et al. Value of C-reactive protein in exacerbation of chronic obstructive pulmonary disease. Respir. Med. 1998; 92: 664-667.Авдеев С.Н., Баймаканова Г.Е. Среактивный белок - новый или старый маркер бронхолегочных инфекций? Атмосфера. Пульмонология и аллергология 2008; 4: 26-32.Авдеев С.Н., Баймаканова Г.Е. Среактивный белок - новый или старый маркер бронхолегочных инфекций? Атмосфера. Пульмонология и аллергология 2008; 4: 26-32.Flanders S.A., Stein J., Shochat G. et al. Performance of a bedside C-reactive protein test in the diagnosis of community-acquired pneumonia in adults with acute cough. Am. J. Med. 2004; 116: 529-535.Flanders S.A., Stein J., Shochat G. et al. Performance of a bedside C-reactive protein test in the diagnosis of community-acquired pneumonia in adults with acute cough. Am. J. Med. 2004; 116: 529-535.Anthonisen N., Manfreda J., Warren C. et al. Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Ann. Int. Med. 1987; 106: 196-204.Anthonisen N., Manfreda J., Warren C. et al. Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Ann. Int. Med. 1987; 106: 196-204.Stockley R.A., O'Brien C., Pye A. et al. Relationship of sputum color to nature and outpatient management of acute exacerbations of COPD. Chest 2000; 117: 1638-1645.Stockley R.A., O'Brien C., Pye A. et al. Relationship of sputum color to nature and outpatient management of acute exacerbations of COPD. Chest 2000; 117: 1638-1645.Murray P.R., Washington J.A. Microscopic and bacteriologic analysis of expectorated sputum. Mayo Clin. Proc. 1975; 50: 339-344.Murray P.R., Washington J.A. Microscopic and bacteriologic analysis of expectorated sputum. Mayo Clin. Proc. 1975; 50: 339-344.Clinical and Laboratory Standards Institute (CLSI). Performance standards for antimicrobial disk susceptibility tests: Approved Standard. 10th ed. www.clsi.org/source/orders/ free/m31-a3.pdf.Clinical and Laboratory Standards Institute (CLSI). Performance standards for antimicrobial disk susceptibility tests: Approved Standard. 10th ed. www.clsi.org/source/orders/ free/m31-a3.pdf.Hurst J.R., Donaldson G.C., Perera W.R. Use of plasma biomarkers at exacerbation of chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2006; 174: 867-874.Hurst J.R., Donaldson G.C., Perera W.R. Use of plasma biomarkers at exacerbation of chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2006; 174: 867-874.Smith R.P., Lipworth B.J. C-reactive protein in simple community-acquired pneumonia. Chest 1995; 107: 1028-1031.Smith R.P., Lipworth B.J. C-reactive protein in simple community-acquired pneumonia. Chest 1995; 107: 1028-1031.Justo D., Lachmi S., Saar N. et al. C-reactive protein velocity following antibiotics in patients with chronic obstructive pulmonary disease exacerbation and community acquired pneumonia. Eur. J. Intern. Med. 2009; 20: 518-521.Justo D., Lachmi S., Saar N. et al. C-reactive protein velocity following antibiotics in patients with chronic obstructive pulmonary disease exacerbation and community acquired pneumonia. Eur. J. Intern. Med. 2009; 20: 518-521.Weis N., Almdal T. Creactive protein - can it be used as a marker of infection in patients with exacerbation of chronic obstructive pulmonary disease. Eur. J. Intern. Med. 2006; 17: 88-91.Weis N., Almdal T. Creactive protein - can it be used as a marker of infection in patients with exacerbation of chronic obstructive pulmonary disease. Eur. J. Intern. Med. 2006; 17: 88-91.Bircan A., Gokirmak M., Kilic O. et al. C-reactive protein levels in patients with chronic obstructive pulmonary disease: role of infection. Med. Princ. Pract. 2008; 17: 202-208.Bircan A., Gokirmak M., Kilic O. et al. C-reactive protein levels in patients with chronic obstructive pulmonary disease: role of infection. Med. Princ. Pract. 2008; 17: 202-208.van Beurden W.J.C., Smeenk F.W.J.M., Harff G.A., Dekhuijzen P.N.R. Markers of inflammation and oxidative stress during lower respiratory tract infections in COPD patients. Monaldi Arch. Chest Dis. 2003; 59: 273-280.van Beurden W.J.C., Smeenk F.W.J.M., Harff G.A., Dekhuijzen P.N.R. Markers of inflammation and oxidative stress during lower respiratory tract infections in COPD patients. Monaldi Arch. Chest Dis. 2003; 59: 273-280.Spruit M.A., Gosselink R., Troosters T. et al. Muscle force during an acute exacerbation in hospitalised patients with COPD and its relationship with CXCL8 and IGF-I. Thorax 2003; 58: 752-756.Spruit M.A., Gosselink R., Troosters T. et al. Muscle force during an acute exacerbation in hospitalised patients with COPD and its relationship with CXCL8 and IGF-I. Thorax 2003; 58: 752-756.Stolz D., Christ-Crain M., Bingisser R. et al. Antibiotic treatment of exacerbations of COPD. A randomized, controlled trial comparing procalcitonin-guidance with standard therapy. Chest 2007; 131: 9-19.Stolz D., Christ-Crain M., Bingisser R. et al. Antibiotic treatment of exacerbations of COPD. A randomized, controlled trial comparing procalcitonin-guidance with standard therapy. Chest 2007; 131: 9-19.Stolz D., Christ-Crain M., Morgenthaler N.G. et al. Copeptin, C-reactive protein, and procalcitonin as prognostic biomarkers in acute exacerbation of COPD. Chest 2007; 131: 1058-1067.Stolz D., Christ-Crain M., Morgenthaler N.G. et al. Copeptin, C-reactive protein, and procalcitonin as prognostic biomarkers in acute exacerbation of COPD. Chest 2007; 131: 1058-1067.Nuralieva G., Avdeev S., Chuchalin A. Time course of systemic inflammatory markers during acute exacerbation of COPD. Eur. Respir. J. 2007; 29 (suppl.): 555s-556s.Nuralieva G., Avdeev S., Chuchalin A. Time course of systemic inflammatory markers during acute exacerbation of COPD. Eur. Respir. J. 2007; 29 (suppl.): 555s-556s.Perera W.R., Hurst J.R., Wilkinson T.M.A. et al. Inflammatory changes, recovery and recurrence at COPD exacerbation. Eur. Respir. J. 2007; 29: 527-534.Perera W.R., Hurst J.R., Wilkinson T.M.A. et al. Inflammatory changes, recovery and recurrence at COPD exacerbation. Eur. Respir. J. 2007; 29: 527-534.

The authors declare that there are no conflicts of interest present.